Insmed, Inc. (INSM): Price and Financial Metrics

Insmed, Inc. (INSM): $21.54

-0.33 (-1.51%)

POWR Rating

Component Grades













Add INSM to Watchlist
Sign Up

Industry: Biotech



in industry


  • Sentiment is the dimension where INSM ranks best; there it ranks ahead of 81.97% of US stocks.
  • The strongest trend for INSM is in Stability, which has been heading down over the past 177 days.
  • INSM ranks lowest in Momentum; there it ranks in the 3rd percentile.

INSM Stock Summary

  • INSMED INC's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than 91.26% of US listed stocks.
  • Of note is the ratio of INSMED INC's sales and general administrative expense to its total operating expenses; only 22.03% of US stocks have a lower such ratio.
  • INSM's price/sales ratio is 11.37; that's higher than the P/S ratio of 90.73% of US stocks.
  • Stocks that are quantitatively similar to INSM, based on their financial statements, market capitalization, and price volatility, are CYTK, FBIO, TVTX, MREO, and PXLW.
  • Visit INSM's SEC page to see the company's official filings. To visit the company's web site, go to

INSM Valuation Summary

  • INSM's price/sales ratio is 11.7; this is 151.61% higher than that of the median Healthcare stock.
  • Over the past 243 months, INSM's EV/EBIT ratio has gone down 8.4.

Below are key valuation metrics over time for INSM.

Stock Date P/S P/B P/E EV/EBIT
INSM 2022-09-23 11.7 58.4 -6.2 -7.7
INSM 2022-09-22 12.0 60.1 -6.4 -7.9
INSM 2022-09-21 12.2 61.1 -6.5 -8.0
INSM 2022-09-20 12.9 64.5 -6.9 -8.4
INSM 2022-09-19 13.1 65.4 -7.0 -8.5
INSM 2022-09-16 12.8 64.0 -6.8 -8.4

INSM Growth Metrics

    Its 3 year net cashflow from operations growth rate is now at -28.96%.
  • Its 2 year net income to common stockholders growth rate is now at -77.5%.
  • The 3 year revenue growth rate now stands at 534.45%.
Over the past 33 months, INSM's revenue has gone up $120,615,000.

The table below shows INSM's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-06-30 221.209 -367.039 -415.958
2022-03-31 201.354 -340.182 -437.634
2021-12-31 188.461 -363.302 -434.654
2021-09-30 173.752 -345.962 -423.889
2021-06-30 170.638 -329.185 -374.834
2021-03-31 167.767 -289.694 -319.367

INSM's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • INSM has a Quality Grade of C, ranking ahead of 31.6% of graded US stocks.
  • INSM's asset turnover comes in at 0.172 -- ranking 207th of 682 Pharmaceutical Products stocks.
  • CYRX, CTLT, and ACOR are the stocks whose asset turnover ratios are most correlated with INSM.

The table below shows INSM's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.172 0.760 -0.609
2021-06-30 0.192 0.753 -0.585
2021-03-31 0.209 0.754 -0.551
2020-12-31 0.206 0.757 -0.513
2020-09-30 0.215 0.776 -0.415
2020-06-30 0.214 0.795 -0.422

INSM Price Target

For more insight on analysts targets of INSM, see our INSM price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $51.78 Average Broker Recommendation 1.4 (Strong Buy)

INSM Stock Price Chart Interactive Chart >

Price chart for INSM

INSM Price/Volume Stats

Current price $21.54 52-week high $34.44
Prev. close $21.87 52-week low $16.41
Day low $21.48 Volume 741,400
Day high $22.47 Avg. volume 1,071,363
50-day MA $24.26 Dividend yield N/A
200-day MA $23.03 Market Cap 2.58B

Insmed, Inc. (INSM) Company Bio

Insmed Incorporated is a biopharmaceutical company focused on developing targeted inhaled therapies for patients suffering from rare lung diseases. The company was founded in 1999 and is based in Bridgewater, New Jersey.

INSM Latest News Stream

Event/Time News Detail
Loading, please wait...

INSM Latest Social Stream

Loading social stream, please wait...

View Full INSM Social Stream

Latest INSM News From Around the Web

Below are the latest news stories about INSMED INC that investors may wish to consider to help them evaluate INSM as an investment opportunity.

Bluebird (BLUE) Surges 15.7%: Is This an Indication of Further Gains?

Bluebird (BLUE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Yahoo | September 22, 2022

Are Investors Undervaluing Insmed Incorporated (NASDAQ:INSM) By 47%?

Does the September share price for Insmed Incorporated ( NASDAQ:INSM ) reflect what it's really worth? Today, we will...

Yahoo | September 18, 2022

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 10 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company.

Yahoo | September 7, 2022

Insmed To Present at Two September Conferences

Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present at the following investor events:

Yahoo | September 6, 2022

Investors bid Insmed (NASDAQ:INSM) up US$686m despite increasing losses YoY, taking five-year CAGR to 19%

The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But when you pick a company...

Yahoo | August 8, 2022

Read More 'INSM' Stories Here

INSM Price Returns

1-mo -14.49%
3-mo 3.11%
6-mo -13.39%
1-year -21.33%
3-year 24.15%
5-year -32.11%
YTD -20.93%
2021 -18.17%
2020 39.41%
2019 82.01%
2018 -57.92%
2017 135.68%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.5851 seconds.